Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients
Numerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/full |
id |
doaj-bac30f3c4b174345b2bdcb51ec70d82d |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kristina Neugebauer Kristina Neugebauer Christine Hammans Christine Hammans Tobias Wensing Vinod Kumar Vinod Kumar Vinod Kumar Wolfgang Grodd Lea Mevissen Lea Mevissen Melanie A. Sternkopf Melanie A. Sternkopf Ana Novakovic Ana Novakovic Ted Abel Ute Habel Ute Habel Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat |
spellingShingle |
Kristina Neugebauer Kristina Neugebauer Christine Hammans Christine Hammans Tobias Wensing Vinod Kumar Vinod Kumar Vinod Kumar Wolfgang Grodd Lea Mevissen Lea Mevissen Melanie A. Sternkopf Melanie A. Sternkopf Ana Novakovic Ana Novakovic Ted Abel Ute Habel Ute Habel Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients Frontiers in Psychiatry schizophrenia nerve growth factor voxel-based morphometry neuroimaging functional decoding |
author_facet |
Kristina Neugebauer Kristina Neugebauer Christine Hammans Christine Hammans Tobias Wensing Vinod Kumar Vinod Kumar Vinod Kumar Wolfgang Grodd Lea Mevissen Lea Mevissen Melanie A. Sternkopf Melanie A. Sternkopf Ana Novakovic Ana Novakovic Ted Abel Ute Habel Ute Habel Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat Thomas Nickl-Jockschat |
author_sort |
Kristina Neugebauer |
title |
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
title_short |
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
title_full |
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
title_fullStr |
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
title_full_unstemmed |
Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia Patients |
title_sort |
nerve growth factor serum levels are associated with regional gray matter volume differences in schizophrenia patients |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Psychiatry |
issn |
1664-0640 |
publishDate |
2019-04-01 |
description |
Numerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether there was a correlation between NGF serum levels and gray matter volume (GMV) in schizophrenia patients. Further, we investigated whether there was an overlap between the correlative findings and cross-sectional GMV differences between schizophrenia patients (n = 18) and healthy controls (n = 19). Serum NGF was significantly correlated to GMV in the left prefrontal lobe, the left midcingulate cortex, and the brainstem in schizophrenia patients. However, we did not find any correlations of NGF serum levels with GMV in healthy controls. Schizophrenia patients showed smaller GMV than healthy controls in brain regions located in the bilateral limbic system, bilateral parietal lobe, bilateral insula, bilateral primary auditory cortex, left frontal lobe, and bilateral occipital regions. In a conjunction analysis, GMV in the left midcingulate cortex (MCC) appears negatively correlated to NGF serum levels in the group of schizophrenia patients and also to be reduced compared to healthy controls. These results suggest an increased vulnerability of schizophrenia patients to changes in NGF levels compared to healthy controls and support a role for NGF signaling in the pathophysiology of schizophrenia. As our pilot study is exploratory in nature, further studies enrolling larger sample sizes will be needed to further corroborate our findings and to investigate the influence of additional covariates. |
topic |
schizophrenia nerve growth factor voxel-based morphometry neuroimaging functional decoding |
url |
https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/full |
work_keys_str_mv |
AT kristinaneugebauer nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT kristinaneugebauer nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT christinehammans nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT christinehammans nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT tobiaswensing nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT vinodkumar nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT wolfganggrodd nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT leamevissen nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT leamevissen nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT melanieasternkopf nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT melanieasternkopf nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT ananovakovic nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT ananovakovic nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT tedabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT utehabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT utehabel nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients AT thomasnickljockschat nervegrowthfactorserumlevelsareassociatedwithregionalgraymattervolumedifferencesinschizophreniapatients |
_version_ |
1724884534963470336 |
spelling |
doaj-bac30f3c4b174345b2bdcb51ec70d82d2020-11-25T02:17:53ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402019-04-011010.3389/fpsyt.2019.00275418237Nerve Growth Factor Serum Levels Are Associated With Regional Gray Matter Volume Differences in Schizophrenia PatientsKristina Neugebauer0Kristina Neugebauer1Christine Hammans2Christine Hammans3Tobias Wensing4Vinod Kumar5Vinod Kumar6Vinod Kumar7Wolfgang Grodd8Lea Mevissen9Lea Mevissen10Melanie A. Sternkopf11Melanie A. Sternkopf12Ana Novakovic13Ana Novakovic14Ted Abel15Ute Habel16Ute Habel17Thomas Nickl-Jockschat18Thomas Nickl-Jockschat19Thomas Nickl-Jockschat20Thomas Nickl-Jockschat21Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyMax-Planck-Institute for Biological Cybernetics, Tübingen, GermanyMax-Planck-Institute for Biological Cybernetics, Tübingen, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyIowa Neuroscience Institute, University of Iowa, Iowa City, IA, United StatesDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, GermanyJülich-Aachen Research Alliance, Jülich, GermanyIowa Neuroscience Institute, University of Iowa, Iowa City, IA, United StatesDepartment of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, United StatesNumerous neuroimaging studies have revealed structural brain abnormalities in schizophrenia patients. There is emerging evidence that dysfunctional nerve growth factor (NGF) signaling may contribute to structural brain alterations found in these patients. In this pilot study, we investigated whether there was a correlation between NGF serum levels and gray matter volume (GMV) in schizophrenia patients. Further, we investigated whether there was an overlap between the correlative findings and cross-sectional GMV differences between schizophrenia patients (n = 18) and healthy controls (n = 19). Serum NGF was significantly correlated to GMV in the left prefrontal lobe, the left midcingulate cortex, and the brainstem in schizophrenia patients. However, we did not find any correlations of NGF serum levels with GMV in healthy controls. Schizophrenia patients showed smaller GMV than healthy controls in brain regions located in the bilateral limbic system, bilateral parietal lobe, bilateral insula, bilateral primary auditory cortex, left frontal lobe, and bilateral occipital regions. In a conjunction analysis, GMV in the left midcingulate cortex (MCC) appears negatively correlated to NGF serum levels in the group of schizophrenia patients and also to be reduced compared to healthy controls. These results suggest an increased vulnerability of schizophrenia patients to changes in NGF levels compared to healthy controls and support a role for NGF signaling in the pathophysiology of schizophrenia. As our pilot study is exploratory in nature, further studies enrolling larger sample sizes will be needed to further corroborate our findings and to investigate the influence of additional covariates.https://www.frontiersin.org/article/10.3389/fpsyt.2019.00275/fullschizophrenianerve growth factorvoxel-based morphometryneuroimagingfunctional decoding |